A Critical Review of New Advances in the Treatment of Schizophrenia

Abstract

Schizophrenia is a chronic mental disorder that is characterized by a wide range of symptoms like hallucination, delusion, paranoia, disorganized speech or behavior, and impairment in cognitive ability. Schizophrenia is a chronic disorder that does not have any cure currently, but the symptoms associated with it can be treated. In the US population, the prevalence of schizophrenia ranges from 0.6% to 1.9%. The pathology of the disease is not completely known, and antipsychotics have certain limitations. In this review, we have concentrated on the pharmacological and non-pharmacological treatment of schizophrenia and new drugs, therapies and treatment options introduced. The adoption of psychosocial therapies has been sluggish and uneven due to insufficient consistency in execution and restricted access to various models of successful treatments. Developing biomarkers for schizophrenia patient segmentation, developing predictive models, enhancing information sharing, and collaboration are potential extra factors. To figure out the direction of medication development for the treatment of schizophrenia, such measures are considered necessary.